BioClinica will be Showcased at Upcoming Industry Conferences

PDF - Adobe Reader Required | RSS | Media Contacts | Investor Contacts

BIOCLINICA WILL BE SHOWCASED AT UPCOMING INDUSTRY CONFERENCES

– Experts to Lead Sessions at Key Global Events –

February 23, 2010

NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services will participate in, and present at, key industry conferences during February and March. Key members of the BioClinica team will participate as expert panelists as well as demonstrate the value of the Company's expanded suite of services at these conferences.
The list of conferences includes:

February 23-24, 2010
Clinical Trial Supply Conference Europe, London
Booth #37

Ed Tourtellotte, Vice President of Product Innovation, will co-present with a member of Johnson & Johnson. They will discuss how BioClinica simulation technology is changing the clinical trial supply manager role with tools for more accurate supply prediction. Their presentation will be held at 10:00 a.m. on February 22 (London) time. BioClinica is a silver sponsor of this conference, which offers the expertise and experience required to meet all the operational, planning, forecasting and manufacturing challenges facing the clinical trial supply field.

March Conferences

March 8 – 10, 2010
22nd Annual Drug Information Association's EuroMeeting, Monaco
Booth #205

This conference brings together more than 3,000 professionals from over 50 countries, including professionals from the biopharmaceutical industry, contract service organizations, academic research centers, regulatory agencies and health ministries. Representatives from the EMEA, FDA and regulatory agencies throughout Europe will be in attendance as well. As BioClinica's global delivery spans 11,000 sites in 88 countries, this conference will showcase its integrated suite of clinical trial services to influential members of the global biopharmaceutical industry.

March 10 – 11, 2010
Imaging in Oncology SMI Conference
London

This conference will focus on a wide range of imaging techniques in a wide range of settings- from preclinical, to clinical, to the future of oncological imaging. Experts will discuss the latest developments in MRI, PET, SPECT, IR, Raman Spectroscopy and more. With twenty years experience in the bioimaging field, BioClinica has a strong footprint in the global industry and can manage every step of the process that begins once a medical image is acquired at a clinical site through the delivery of evaluated results to the sponsor. This end-to-end control will ensure that the process is as efficient and expedient as possible.

March 17 – 18, 2010
Outsourcing in Clinical Trials New Jersey
New Brunswick, New Jersey
Booth #15

Bringing together major pharma and biotech manufacturers to debate potential solutions to complex challenges, this event will cover topics such as vendor selection, the effect of mergers and acquisitions on the outsourcing marketplace, offshoring and relationship management. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial services and co-present an outsourcing case study.

March 21 -23, 2010
ACDM (Association for Clinical Data Management) Annual Conference
Northamptonshire, UK
Booth # TBD

Jonathan Andrus, Vice President of Data & Study Operations will speak on ways to ensure data quality in an EDC environment at 2:25 p.m. (London) on March 23, 2010. The presentation will provide examples and an overall case study that will help bring the material to life and provide real world best practices.

March 22-24, 2010
Midwest Clinical Suppliers Group Meeting
Hyatt Regency Hill Country Resort & Spa, San Antonio, Texas

Nick Lenares, Chief Software Architect for BioClinica Optimizer, will co-facilitate the Forecasting and Planning to Eliminate Waste workshop. Panelists will provide an overview of business cases for procuring forecasting and planning tools, describe the benefits that result from using forecasting and planning tools and give examples of real-life situations where a forecasting tool was used.

March 30, 2010
Current and Innovative Imaging Biomarkers in Neurology and Oncology Drug Development Complimentary Symposium
Princeton, New Jersey

BioClinica is pleased to present a complimentary symposium addressing the Current and Innovative Imaging Biomarkers in Neurology and Oncology Drug Development. The venue for this in-depth symposium is located at the Princeton Marriott Hotel & Conference Center at Forrestal in Princeton, NJ from 8:00 a.m. - 4:30 p.m.

James Dorsey, Vice President of Marketing said, "These global events provide BioClinica with a great opportunity to share the expertise we've accumulated through twenty years of experience and to highlight our best-in-class suite of integrated clinical trial technologies and services and their benefits to our customers."

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.